The National Comprehensive Cancer Network® (NCCN) and Pfizer Global Medical Grants are collaborating to offer a new grant opportunity seeking proposals for investigator-sponsored research with elranatamab. Pfizer (hereafter, “Grantor”) is providing research grants to support clinical research studies to further evaluate the effectiveness of elranatamab in the treatment of Multiple Myeloma.
Studies evaluating the BCMA bispecific antibody elranatamab to advance the treatment of MM and toxicity management including, but not limited to:
Estimated Total Program Funding: